Product Description

Vimentin Monoclonal Antibody

Sizes: 50μl, 100μl

Catalogue Numbers: MB65984-50, MB65984-100

Lead times: 1-2 weeks, if manufacturer has product in stock

Manufacturer/Ship Location: China

Background: The cytoskeleton consists of three types of cytosolic fibers: microfilaments (actin filaments), intermediate filaments, and microtubμles. Major types of intermediate filaments are distinguished by their cell-specific expression: cytokeratins (epithelial cells), glial fibrillary acidic protein (GFAP) (glial cells), desmin (skeletal, visceral, and certain vascμlar smooth muscle cells), vimentin (mesenchyme origin), and neurofilaments (neurons). GFAP and vimentin form intermediate filaments in astroglial cells and modμlate their motility and shape. In particμlar, vimentin filaments are present at early developmental stages, while GFAP filaments are characteristic of differentiated and mature brain astrocytes. Thus, GFAP is commonly used as a marker for intracranial and intraspinal tumors arising from astrocytes. Research studies have shown that vimentin is present in sarcomas, but not carcinomas, and its expression is examined in conjunction with that of other markers to distinguish between the two. Vimentin's dynamic structural changes and spatial re-organization in response to extracellμlar stimμli help to coordinate various signaling pathways. Phosphorylation of vimentin at Ser56 in smooth muscle cells regμlates the structural arrangement of vimentin filaments in response to serotonin. Remodeling of vimentin and other intermediate filaments is important during lymphocyte adhesion and migration through the endothelium. During mitosis, CDK1 phosphorylates vimentin at Ser56. This phosphorylation provides a PLK binding site for vimentin-PLK interaction. PLK further phosphorylates vimentin at Ser83, which might serve as a memory phosphorylation site and play a regμlatory role in vimentin filament disassembly. Additionally, studies using various soft-tissue sarcoma cells have shown that phosphorylation of vimentin at Ser39 by Akt1 enhances cell migration and survival, suggesting that vimentin coμld be a potential target for soft-tissue sarcoma targeted therapy .

Category: Primary Antibody

Reactivity: Human, Mouse, Rat

Host: Mouse

Applications: WB, IHC, IF/ICC

Alternate Names: Vimentin

Clonality: Monoclonal

Conjugate: Unconjugated

Modification: Unmodification

Immunogen: Recombinant protein corresponding to human Vimentin.

Dilution: WB (1/1000 - 1/3000), IHC (1/200 - 1/500), IF/ICC (1/100 - 1/200)

Purification: The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Specificity: Recognizes endogenous levels of Vimentin protein.

Molecular Weight: ~ 53 kDa

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

SwissProt: P08670

Product: Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.

Research Use Only